About
Intelligence at the speed of discovery
Compressing the timeline from hypothesis to approved therapy.
8
Core Engines
24/7
Autonomous Ops
3
Continents
2026
Founded
Mission
“Every day of delay is a day patients wait. Every dollar wasted on inefficient tools is diverted from discovery.”
The clinical trial industry runs on infrastructure built decades ago. TrialDataX.AI replaces disconnected point solutions with a unified intelligence layer.
Origin
Built from research. Designed for production.
Born from doctoral AI research in temporal deep learning and clinical optimization. Every model, pipeline, and engine built from zero. Vertically integrated — no third-party assemblies.
Intellectual Property
Patent-pending innovation
USPTO provisional filings protecting 8 core innovations.
Milestones
2023
Research Genesis
Doctoral AI research identifies temporal deep learning as a key lever for trial optimization.
2024
Platform Architecture
Core engines built from scratch. No third-party APIs.
2025
Production Launch
8 AI engines, adaptive analytics, and CTDM marketplace go live.
2026
Incorporation
Delaware C-Corp. 23 Ventures joins. Engineering across three continents.
Company
TrialDataX.AI Inc.
Delaware C-Corp, formed April 2026. Backed by 23 Ventures and institutional relationships spanning North America, Europe, and Asia. Leadership includes Richard C.E. Morgan (co-founder of Celgene, 40+ life science companies) as Executive Chairman. Team from Google, Columbia, LBS, and MIT.